BIND is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called Accurins™. We seek to significantly improve patients' lives and treat disease in a powerful new way by designing Accurins to selectively accumulate at the site of disease, dramatically enhancing efficacy while minimizing effects on healthy tissues.

Accurins hold extraordinary potential for developing best-in-class drugs that improve patient outcomes across a broad range of disease areas. We are using our Medicinal Nanoengineering® platform to create a pipeline of proprietary Accurins that have demonstrated unique properties for targeting disease. In addition, we are developing Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential with optimized properties and to transform the performance of important existing drug products.